Eden review (2026): pricing, programs, pros & limitations

The numbers behind this page

Eden on tirzepatide: $298 a month

Eden sits 7 of 12 programmes we can price for standard-dose tirzepatide, at $298 a month. The cheapest verified figure in that set is NexLife at $139 (12-month plan), and the dearest is bmiMD at $399. The median is $298, so this programme sits exactly at the middle of the market.

6 programmes in our dataset come in cheaper on tirzepatide. Against the cheapest, the gap is $159 a month, or $1,908 across a year — a 53% difference. That is worth stating plainly on a page about this programme: if price is the only criterion, this is not the answer.

The conditions attached to that figure: $199 med (flat at every dose) + $99 membership (REQUIRED). Provider Reported

Across a first year at this rate the medication cost alone is $3,576, before any laboratory work a programme requires and before the months spent below a maintenance dose during titration. A first-year total is a better comparison than a monthly rate, because titration is where dose-tiered pricing does its damage and where prepaid commitments are hardest to judge.

Eden on semaglutide: $198 a month

Eden sits 7 of 12 programmes we can price for standard-dose semaglutide, at $198 a month. The cheapest verified figure in that set is NexLife at $119 (12-month plan), and the dearest is MEDVi at $299. The median is $198, so this programme sits exactly at the middle of the market.

6 programmes in our dataset come in cheaper on semaglutide. Against the cheapest, the gap is $79 a month, or $948 across a year — a 40% difference. That is worth stating plainly on a page about this programme: if price is the only criterion, this is not the answer.

The conditions attached to that figure: $99 med (flat at every dose) + $99 membership. Membership REQUIRED for any medication. Provider Reported

Across a first year at this rate the medication cost alone is $2,376, before any laboratory work a programme requires and before the months spent below a maintenance dose during titration. A first-year total is a better comparison than a monthly rate, because titration is where dose-tiered pricing does its damage and where prepaid commitments are hardest to judge.

The two molecules at Eden

Tirzepatide runs $298 a month here against $198 for semaglutide, a difference of $100 a month or $1,200 across a year for the same clinicians, the same fulfilment and the same billing structure.

That gap is structural rather than promotional. Tirzepatide's active ingredient costs more to source, the peptide is harder to synthesise, and fewer compounding pharmacies are equipped to produce it. Where a programme prices the two identically, that is a commercial decision rather than a change in what the medicine costs to make, and it is worth asking what else changed alongside it.

Whether the premium is worth $1,200 a year is a clinical question rather than a pricing one. The head-to-head evidence favours tirzepatide on mean weight reduction; semaglutide carries the larger cardiovascular outcomes base. If cost is the binding constraint, the cheaper molecule you can sustain for three years is a better bet than the dearer one you stop after eight months, because weight returns when either drug stops.

Checking the figures in Eden

The figure on this page for Eden is $198 a month, captured 2026-09-04. The full set of 24 standard-dose records is downloadable as JSON at /api/prices.json, with molecule and dose class stated on every record. Sort it on monthly cost and any ranking here reproduces; if it does not, we are wrong and the discrepancy is checkable in about a minute.

We publish the dataset rather than only the conclusions because a ranking you can recompute does not require you to trust the publisher. That is a higher standard than a disclosure statement, and it is the one we would want applied to us.

Reading the price against the market

Eden on tirzepatide over a longer horizon

At $298 a month, medication alone costs $3,576 across one year, $10,728 across three and $17,880 across five. Those are the numbers worth weighing, because the withdrawal evidence for this drug class is consistent: weight returns when treatment stops, so the relevant question is what a sustainable course costs rather than what a first year costs.

Put differently, a programme you can afford for five years at $298 a month is a better clinical bet than one you can afford for eight months at a lower rate. Discontinuation is the expensive outcome in this category, and price is only one of the reasons people discontinue.

Eden on semaglutide over a longer horizon

At $198 a month, medication alone costs $2,376 across one year, $7,128 across three and $11,880 across five. Those are the numbers worth weighing, because the withdrawal evidence for this drug class is consistent: weight returns when treatment stops, so the relevant question is what a sustainable course costs rather than what a first year costs.

Put differently, a programme you can afford for five years at $198 a month is a better clinical bet than one you can afford for eight months at a lower rate. Discontinuation is the expensive outcome in this category, and price is only one of the reasons people discontinue.

What sits either side of Eden on tirzepatide

Immediately cheaper is Enhance.MD at $280 a month, $18 below this programme, or $216 across a year. A gap that size is worth checking the conditions on before treating it as a saving: 12-month plan. Same price at all doses. 6-month $296; 3-month $313; month-to-month $329. Provider Reported

Immediately dearer is Noom Med at $299, $1 above, or $12 a year. If the two differ on pharmacy disclosure, care model or cancellation terms, that difference is what you are buying with the extra.

Ranking neighbours matter more than the top of a list. Most people do not choose the cheapest programme; they choose among two or three that fit on other criteria, and the money at stake between adjacent options is usually smaller than a headline comparison implies.

What sits either side of Eden on semaglutide

Immediately cheaper is Henry Meds at $179 a month, $19 below this programme, or $228 across a year. A gap that size is worth checking the conditions on before treating it as a saving: Sublingual tablets or drops, absorbed under the tongue. All-inclusive. Provider Reported

Immediately dearer is Noom Med at $199, $1 above, or $12 a year. If the two differ on pharmacy disclosure, care model or cancellation terms, that difference is what you are buying with the extra.

Ranking neighbours matter more than the top of a list. Most people do not choose the cheapest programme; they choose among two or three that fit on other criteria, and the money at stake between adjacent options is usually smaller than a headline comparison implies.

Where this sits in the market

Eden prices semaglutide at $198 a month, $0 level with the $198 median across 12 programmes. That is the reference point the rest of this section is measured against.

12 programmes publish a price for both molecules. Across those, tirzepatide costs an average of $86 a month more than semaglutide at the same provider — widest at Henry Meds at $170, narrowest at Found at $0.

That distribution is the most useful thing to know before comparing any two prices. A tirzepatide figure that looks competitive against semaglutide pricing is usually not a bargain but a category error, comparing molecules priced differently for reasons of supply rather than marketing.

Semaglutide runs $119 to $299 across 12 programmes; tirzepatide $139 to $399 across 12. Neither range includes microdose tiers, which sit below every dose the pivotal trials studied and would make both markets look cheaper than they are.

Where this sits in the market

Eden prices semaglutide at $198 a month, $0 level with the $198 median across 12 programmes. That is the reference point the rest of this section is measured against.

12 programmes publish a price for both molecules. Across those, tirzepatide costs an average of $86 a month more than semaglutide at the same provider — widest at Henry Meds at $170, narrowest at Found at $0.

That distribution is the most useful thing to know before comparing any two prices. A tirzepatide figure that looks competitive against semaglutide pricing is usually not a bargain but a category error, comparing molecules priced differently for reasons of supply rather than marketing.

Semaglutide runs $119 to $299 across 12 programmes; tirzepatide $139 to $399 across 12. Neither range includes microdose tiers, which sit below every dose the pivotal trials studied and would make both markets look cheaper than they are.

Questions this page answers

Is Eden the cheapest tirzepatide option?

No. NexLife is cheaper at $139 a month on its 12-month plan, $159 below Eden, or $1,908 across a year.

What does a year of tirzepatide at Eden cost?

About $3,576 in medication at $298 a month, before any required laboratory work and before the months spent below a maintenance dose during titration. Over three years that is $10,728.

How much does Eden charge for compounded semaglutide?

$198 a month at a standard therapeutic dose, captured 2026-09-04. $99 med (flat at every dose) + $99 membership. Membership REQUIRED for any medication. Provider Reported That places it 7 of 12 programmes we can price for semaglutide.

Is Eden the cheapest semaglutide option?

No. NexLife is cheaper at $119 a month on its 12-month plan, $79 below Eden, or $948 across a year.

What does a year of semaglutide at Eden cost?

About $2,376 in medication at $198 a month, before any required laboratory work and before the months spent below a maintenance dose during titration. Over three years that is $7,128.

How much does Eden charge for compounded tirzepatide?

$298 a month at a standard therapeutic dose, captured 2026-09-04. $199 med (flat at every dose) + $99 membership (REQUIRED). Provider Reported That places it 7 of 12 programmes we can price for tirzepatide.